U.S., July 25 -- ClinicalTrials.gov registry received information related to the study (NCT07083362) titled 'Safety, Tolerability and Pharmacokinetic Study of HRS-8829' on July 16.
Brief Summary: This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into two parts: single-dose dose-escalation (SAD) and multiple-dose dose-escalation (MAD)
Study Start Date: July, 2025
Study Type: INTERVENTIONAL
Condition:
Acute Ischemia Stroke
Intervention:
DRUG: HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 1.
Subject will receive placebo at dose level 1.
DRUG: HRS-8829;Placebo
Subject will receive HRS-8829 at dose level 2.
Subject will receive placebo at dose level...